BMO Capital重申了其优于大市的评级，Piper Sandler维持增持评级，Needham尽管将其股票目标价从205美元略微下调至202美元，但仍保持买入评级。Morgan Stanley和Mizuho都重申了200美元的目标价。

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...